Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma | Zendy

Keith T. Flaherty | Zendy; Sandra J. Lee | Zendy; Fengmin Zhao | Zendy; Lynn M. Schuchter | Zendy; Lawrence E. Flaherty | Zendy; Richard Kefford | Zendy; Michael B. Atkins | Zendy; Philip D. Leming | Zendy; John M. Kirkwood | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

Author(s) -

Keith T. Flaherty,

Sandra J. Lee,

Fengmin Zhao,

Lynn M. Schuchter,

Lawrence E. Flaherty,

Richard Kefford,

Michael B. Atkins,

Philip D. Leming,

John M. Kirkwood

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.42.1529

Subject(s) - medicine , carboplatin , clinical endpoint , rash , paclitaxel , chemotherapy , neutropenia , placebo , phases of clinical research , melanoma , oncology , urology , gastroenterology , randomized controlled trial , surgery , cisplatin , pathology , alternative medicine , cancer research

The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive patients with metastatic melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research